Clinical significance of GPR56, transglutaminase 2, and NF-κB in esophageal squamous cell carcinoma

Cancer Investigation

Volumn 29, Issue 1, 2011, Pages 42-48

  Kausar, Tasneem ^a   Sharma, Rinu ^b   Hasan, Md Raghibul ^a   Tripathi, Satyendra Chandra ^a   Saraya, Anoop ^a   Chattopadhyay, Tushar K ^a   Gupta, Siddartha Datta ^a   Ralhan, Ranju ^c,d,e  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b GURU GOBIND SINGH INDRAPRASTHA UNIVERSITY   (India)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Esophageal cancer; GPR56; NF B; Transglutaminase 2

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 56; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INVASION; CANCER PATIENT; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADULT; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIA; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NF-KAPPA B; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED; TISSUE ARRAY ANALYSIS; TRANSGLUTAMINASES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 78650471817     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.512597     Document Type: Article

References (45)

1. International Agency for Research on Cancer. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalance Worldwide, Version 1.0, IARC Cancer Base No. 5. Lyon, France: IARC Press, 2005.
2. Malkan G, Mohandas KM. Epidemiology of digestive cancers in India. I. General principles and esophageal cancer. Indian J Gastroenterol 1997;3:98-102.
3. Gajalakshmi V, Swaminathan R, Shanta V. An independent survey to assess completeness of registration: population based cancer registry, Chennai, India. Asian Pac J Cancer Prev 2001;3:179-183.
4. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 1996;3:225-235.
5. ParkinDM, Bray F, Ferlay J, Pisani P. Estimating theworld cancer burden: Globocan 2000. Int J Cancer 2001;2:153-156.
6. GuptaNM, Jindal R, PrakashO,Gupta R, BhasinDK.Comparison of the clinical profile and outcome for squamous cell carcinoma and adenocarcinoma of the distal esophagus and cardia in India. Surg Today 2001;5:400-404.
7. Yeole BB, Kumar AV. Population-based survival from cancers having a poor prognosis inMumbai (Bombay), India. Asian Pac J Cancer Prev 2004;2:175-182.
8. Chandrashekar R, Tsuji N, Morales T, Ozols V, Mehta K. An ERp60-like protein from the filarial parasite Dirofilaria immitis has both transglutaminase and protein disulfide isomerase activity. Proc Natl Acad Sci USA 1998;95:531-536.
9. Mehta K. Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 2005;38:1-18.
10. AeschlimannD,ThomazyV. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 2000;41:1-27.
11. Milakovic T, Tucholski J,McCoy E, JohnsonGV. Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 2004;279:8715-8722.
12. Mishra S,Murphy LJ.The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 2006;339:726-730.
13. Mishra S, Saleh A, Espino PS, Davie JR, Murphy LJ. Phosphorylation of histones by tissue transglutaminase. J Biol Chem 2006;281:5532-5538.
14. Singh US, Pan J, Kao YL, Joshi S, Young KL, Baker KM. Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem 2003;278:391-399.
15. Fok JY, Ekmekcioglu S, Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol CancerTher 2006;5:1493-1503.
16. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007;26:2459-2470.
17. Verma A, Wang H, Manavathi B. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006;66:10525-10533.
18. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008;68:5849-5858.
19. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kappaB in development and progression of human cancer. Virchows Arch 2005;446:475-482.
20. Zandi E, Karin M. Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. Mol Cell Biol 1999;19:4547-4551.
21. Ahn KS, Sethi G, Aggarwal BB. Nuclear factor-kappa B: from clone to clinic. Curr Mol Med 2007;7:619-637.
22. Liu M, Parker RM, Darby K, Eyre HJ, Copeland NG, Crawford J, GilbertDJ, Sutherland GR, JenkinsNA,HerzogH. GPR56, a novel secretin-like human G-protein-coupled receptor gene. Genomics 1999;55:296-305.
23. Fredriksson R, Lagerstrom MC, Hoglund PJ, Schioth HB. Novel human G protein-coupled receptors with long N-terminals containing GPS domains and Ser/Thr-rich regions. FEBS Lett 2002;531:407-414.
24. Fredriksson R,GloriamDE,Hoglund PJ, LagerstromMC, Schioth HB. There exist at least 30 human G-protein-coupled receptors with long Ser/Thr-rich N-termini. Biochem Biophys Res Commun 2003;301:725-734.
25. Bjarnadottir TK, Fredriksson R, Hoglund PJ, Gloriam DE, Lagerstrom MC, Schioth HB. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. Genomics 2004;84:23-33.
26. Bjarnadottir TK, Fredriksson R, Schioth HB. The adhesion GPCRs: a unique family of G protein-coupled receptors with important roles in both central and peripheral tissues. Cell Mol Life Sci 2007;64:2104-2119.
27. Piao X, Hill RS, Bodell A, Chang BS, Basel-Vanagaite L, Straussberg R, Dobyns WB, Qasrawi B, Winter RM, Innes AM, Voit T, Ross ME, Michaud JL, Descarie JC, Barkovich AJ, Walsh CA. G protein-coupled receptor-dependent development of human frontal cortex. Science 2004;303:2033-2036.
28. Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, Cummins J, Nikolich K, Urfer R, Foehr ED. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 2005;24:1673-1682.
29. Ke N, Sundaram R, Liu G, Chionis J, Fan W, Rogers C, Awad T, Grifman M, Yu D, Wong-Staal F, Li QX. Orphan G proteincoupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway. Mol Cancer Ther 2007;6:1840-1850.
30. Sud N, Sharma R, Ray R, Chattopadhyay TK, Ralhan R. Differential expression of G-protein coupled receptor 56 in human esophageal squamous cell carcinoma. Cancer Lett 2006;233:265-270.
31. Mehta K, Fok JY,Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004;10:8068-8076.
32. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer 1994;58:400-406.
33. Herman JF, Mangla LS, Mehra K. Implication of tissue transglutaminase (TG2) expression in drug resistant breast cancer (MCF- 7) cells. Oncogene 2006;25:3049-3058.
34. Kim DS, Park SS, Nam BH. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factorkB inactivation. Cancer Res 2006;66:10936-10943.
35. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemo radiotherapy. Ann Surg 2004;239:491-500.
36. Wang W,Abbruzzese AL, EvansDB, Larry L,Cleary KR,Chiao PJ. The nuclear factor-?B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-127.
37. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonensheinet GE. Aberrant nuclear factor-?B/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-2960.
38. Bours V, Dejardin E, Goujon-Letawe F,MervilleMP, Castronovo V. The NF-?B transcription factor and cancer: high expression of NF-kB- and IkB-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145-149.
39. Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, Deo SV, Shukla NK, Aggarwal BB, Ralhan R. Expression of NF- ?B parallels Cox2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer 2007;120:2545-2556.
40. Lee J; Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY. Transglutaminase 2 induces nuclear factor-?B activation via a novel pathway in BV-2 microglia. J Biol Chem 2004;279:53725-53735.
41. MannAP, VermaA, Sethi G, Manavathi B,WangH, Fok JY,Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-?B in cancer cells: delineation of a novel pathway. Cancer Res 2006;66:8788-8795.
42. Kim DS, Park SS, Nam BH, Kim IH, Kim SY. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-?B inactivation. Cancer Res 2006;66:10936-10943.
43. Jin Z, Tietjen I, Bu L, Liu-Yesucevitz L, Gaur SK, Walsh CA, Piao X. Disease-associated mutations affect GPR56 protein trafficking and cell surface expression. Hum Mol Genet 2007;16:1972-1985.
44. Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A 2006;103:9023-9028.
45. Iguchi T, Sakata K, Yoshizaki K, Tago K, Mizuno N, Itoh H. Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway. J Biol Chem 2008;283:14469-14478.